Yarrow Bioscience prices $161.8M stock offering, expected to close Sept 14
The company sold 5,769,231 shares at $26.00 each after underwriters fully exercised their option, with closing expected September 14, 2026.
SEC filing
Latest
5 stories
Monday, September 14
Thursday, August 13
Yarrow Bioscience files amended 8-K with Pre-Merger Yarrow financials after VYNE merger
The filing adds recast financial statements, pro forma results, and an August 13, 2026 quarterly release, covering the entity now known as Yarrow Bioscience Operating Company Corp.
SEC filing
Tuesday, July 28
Yarrow Bioscience details Phase 2a/2b trial design, merger share counts after VYNE closing
New 8-K filing adds trial specifics, share totals, and merger mechanics for the combined company now trading as YARW.
SEC filing
Tuesday, July 21
VYNE approves 1-for-50 reverse split, sets special dividend ahead of Yarrow merger
VYNE Therapeutics will pay a $17.3 million cash dividend and complete a reverse stock split before its merger with Yarrow Bioscience closes around July 24, 2026.
SEC filing
Friday, July 10
VYNE declares special dividend tied to pending Yarrow Bioscience merger
VYNE Therapeutics set a $16.5 million cash dividend ahead of its planned merger with Yarrow, with closing expected around July 24, 2026.
SEC filing